 The dose escalation phase is designed to characterize the safety and tolerability of the combination of enoblituzumab and ipilimumab and to define the maximum tolerated or administered dose MTDMAD in patients with B7-H3 expressing mesothelioma, urothelial cancer, NSCLC, SCCHN, Clear cell renal cell carcinoma ccRCC, ovarian cancer, melanoma, thyroid cancer, Triple negative breast cancer TNBC, pancreatic cancer, colon cancer, soft tissue sarcoma, or prostate cancer. 